Analysis measures cerebrospinal fluid catecholamines in Alzheimer's and frontotemporal dementia, highlighting potential clinical links.
Aims Catecholamine analysis and studies to modulate dopamine and norepinephrine in dementia have had contradictory results. We aimed to analyze the cerebrospinal fluid (CSF) levels of L-DOPA, dopamine, and norepinephrine of patients with Alzheimer's disease (AD), frontotemporal dementia (FTD) and normal controls (NC), and their relationship with clinical variables.
No takes yet. Share an insight, caveat, or question.
Moreira et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: